title: Thalidomide maintenance in multiple myeloma: certainties and controversies.
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Lucia
authors.initials: L
authors.lastname: Pantani
authors.forename: Paola
authors.initials: P
authors.lastname: Tacchetti
authors.forename: Maria Caterina
authors.initials: MC
authors.lastname: Pallotti
authors.forename: Annamaria
authors.initials: A
authors.lastname: Brioli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Petrucci
authors.forename: Elena
authors.initials: E
authors.lastname: Zamagni
authors.forename: Patrizia
authors.initials: P
authors.lastname: Tosi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D011239:Prednisolone / Q000008:administration & dosage; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage*; D014182:Transplantation, Autologous
chemical_list: D005938:Glucocorticoids; D013792:Thalidomide; D011239:Prednisolone; D008558:Melphalan